1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Opioid Induced Side Effects - Pipeline Review, H1 2014

Opioid Induced Side Effects - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 41 pages

Opioid Induced Side Effects - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Opioid Induced Side Effects - Pipeline Review, H1 2014’, provides an overview of the Opioid Induced Side Effects’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid Induced Side Effects, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid Induced Side Effects and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opioid Induced Side Effects
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Opioid Induced Side Effects and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Opioid Induced Side Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid Induced Side Effects pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid Induced Side Effects
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid Induced Side Effects pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Opioid Induced Side Effects - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Opioid Induced Side Effects Overview 6
Therapeutics Development 7
Pipeline Products for Opioid Induced Side Effects - Overview 7
Pipeline Products for Opioid Induced Side Effects - Comparative Analysis 8
Opioid Induced Side Effects - Therapeutics under Development by Companies 9
Opioid Induced Side Effects - Therapeutics under Investigation by Universities/Institutes 11
Opioid Induced Side Effects - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Opioid Induced Side Effects - Products under Development by Companies 14
Opioid Induced Side Effects - Products under Investigation by Universities/Institutes 15
Opioid Induced Side Effects - Companies Involved in Therapeutics Development 16
Shionogi and Co., Ltd. 16
Cortex Pharmaceuticals, Inc. 17
Charleston Laboratories, Inc. 18
Opioid Induced Side Effects - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
naldemedine - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
CL-108 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CX-2007 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
CX-2076 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
CLH-5 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
CLH-10 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
OFQ Peptide - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Opioid Induced Side Effects - Recent Pipeline Updates 34
Opioid Induced Side Effects - Dormant Projects 36
Opioid Induced Side Effects - Product Development Milestones 37
Featured News and Press Releases 37
May 19, 2014: Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product 37
Dec 09, 2013: Acura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug Development 37
Jul 18, 2013: Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables

Number of Products under Development for Opioid Induced Side Effects, H1 2014 7
Number of Products under Development for Opioid Induced Side Effects - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Opioid Induced Side Effects - Pipeline by Shionogi and Co., Ltd., H1 2014 16
Opioid Induced Side Effects - Pipeline by Cortex Pharmaceuticals, Inc., H1 2014 17
Opioid Induced Side Effects - Pipeline by Charleston Laboratories, Inc., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Opioid Induced Side Effects Therapeutics - Recent Pipeline Updates, H1 2014 34
Opioid Induced Side Effects - Dormant Projects, H1 2014 36

List of Figures

Number of Products under Development for Opioid Induced Side Effects, H1 2014 7
Number of Products under Development for Opioid Induced Side Effects - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

North America Opioid Market Analysis By Product, By Application And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, ...

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA

  • $ 3080
  • Industry report
  • September 2016
  • by MP Advisors

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing ...

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese N, N-diethyl-p-phenylenediamine hydrochloride Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global N, N-dieth ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Related Market Segments :

Opioid
Pharmaceutical

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.